Quarterly Earnings

Don't let headline numbers fool you. True North's Q2 reveals a 7.1% NOI surge and 96% occupancy, a testament to its sharp portfolio management.

Kyntra Bio's Q2 profit was driven by a one-time accounting gain, masking operating losses. Now, the firm bets its future on two critical Q4 data readouts.

Plunging revenues and a staggering net loss push IM Cannabis to the edge, forcing a desperate and bizarre strategic pivot from medical marijuana to military drones.

With a cash runway to 2029 and a novel cancer drug nearing key data, NuCana signals quiet confidence in a high-stakes race to treat resistant melanoma.

Soluna Holdings reports a 145% revenue surge but a widening net loss, revealing a bold strategy to trade short-term profits for a vast green AI infrastructure.

After years of losses, Smith Micro's Q2 results show a dramatic improvement in profitability, driven by deep cost cuts and a strategic shift beyond carriers.

With a $115M financing and an expanded pipeline, Assembly Biosciences is betting on novel therapies for liver and viral diseases. But can it navigate a crowded field?

The InsurTech firm posted a Q2 loss and falling revenue, but its forward-looking metrics tell a different story. A deep dive into a high-stakes bet on AI.

With over $1B in cash, Nektar is pushing its novel drug, rezpegaldesleukin, into final trials. It's a high-stakes bet on a new era for autoimmune care.

Inhibrx Biosciences lands a massive new loan to fuel its promising cancer drug trials, but rising costs and a wider net loss paint a high-stakes picture.

Amid rising costs, Trust Stamp pivots to the $48B Sovereign-AI market and a key EU semiconductor project, signaling a strategic shift to national tech security.

Quebec's pension giant posted a 5.1% mid-year return, trailing its benchmark as an AI boom lifted public stocks while pressuring private equity valuations.

Onterris's $9M in new awards from a major energy client highlights a two-decade partnership, but can its tech-driven environmental solutions navigate the sector's volatile transition?

With strong Q2 results as a tailwind, Interlink is making a bold move with a transformative acquisition and new sensor tech. But can it execute?

Saga Communications reports falling revenues and operating losses, yet its digital arm surges. A deep dive into the broadcaster's high-stakes balancing act.

Orbit International's Q2 report shows deepening losses from contract delays, but a rising backlog and stronger margins in key divisions suggest a complex path to recovery.

Advanced Flower Capital's Q2 saw Net Asset Value rise, thanks to a savvy share buyback. But a drop in net investment income reveals a complex transition.

Abeona Therapeutics celebrates rising sales for its life-changing RDEB therapy, ZEVASKYN. But behind the numbers lies a story of manufacturing hurdles and mounting debt.

Revenue is down, but Bragg Gaming's margins are up. A new chairman, a major acquisition, and deep cuts signal a high-stakes bet on a leaner future.

NeuPath Health's Q2 results show headline declines, but a deeper look reveals strong organic growth from record patient visits and strategic expansion.